Precigen Inc. (NASDAQ:PGEN) does about 2.11M shares in volume on a normal day but saw 3819959 shares change hands in Friday trading. The company now has a market cap of 959.78M USD and an enterprise value of about $1.08B. Its current market price is $6.09, marking an increase of 9.34% compared to the previous close of $5.57. The 52 week high reached by this stock is $7.28 whilst the lowest price level in 52 weeks is $1.26. The script in recent trading has seen the stock touch a high of $6.65 and a low of $5.56.
Precigen Inc. (PGEN) has a 20-day trading average at $4.74 and the current price is -16.35% off the 52-week high compared with 383.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.68 and its 200-day simple moving average is $4.36. If we look at the stock’s price movements over the week, volatility stands at 12.04%, which decreases to 10.27% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 68.22 to suggest the stock is neutral.
The consensus objective for the share price is $9.33, suggesting that the stock has a potential upside of 34.73% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 08, 2020 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $5.
The current price level is 31.06%, 31.51%, and 39.92% away from its SMA20, SMA50, and SMA200 respectively, with the PGEN price moving below the 50-day SMA on August 21. Precigen Inc. (PGEN) stock is up 36.85% over the week and 36.85% over the past month. Its price is 11.13% year-to-date and 3.75% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.26 below consensus estimates by -$0.13. PGEN’s earnings per share are forecast to grow by 59.80% this year and 40.80% over next year. Expected sales for next quarter are $15.56 million, which analysts say will come at $88.89 million for the current fiscal year and next year at $84.82 million. In addition, estimates put the company’s current quarterly revenue at an average of $13.05 million.
To reach the target analysts have set, the stock logically needs to grow 34.73 percent from here.
Outstanding shares total 164.07M with insiders holding 15.48% of the shares and institutional holders owning 75.62% of the company’s common stock. The company has a return on investment of -69.70% and return on equity of -295.00%. The beta has a value of 1.55. Price to book ratio is 20.30 and price to sales ratio is 10.47.
According to a U.S. Securities and Exchange Commission filing, Miller Opportunity Trust has added its position in Precigen Inc. (PGEN) to 5,900,000 shares, mirroring a recent increase by 18.00%. Miller Opportunity Trust added 0.9 million shares of Precigen Inc. common stock bringing its total worth to about $24.84 million at the end of recent close, SEC documents show. Miller Opportunity Trust isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 0.0 shares to end up with 1,867,600 shares worth $7.86 million. iShares NASDAQ Biotechnology ETF cut their holdings by -0.77% in the company over the course of the most recent quarter. It now holds a 1.03% position in Precigen Inc. thanks to 1.78 million shares amounting to $7.49 million.